Lymphoma
| Primary Site | Histology | Behavior | Schema Discriminator 1 |
|---|---|---|---|
| C000-C424, C470-C509, C511-C608, C619-C631, C637-C689, C691-C694, C698-C699, C739-C749, C760-C809 | 9590, 9596-9663, 9673-9699, 9702-9719, 9725-9726, 9735, 9737-9738 | <Any value> | |
| C440, C442-C449, C510, C609, C632 | 9590, 9596, 9650-9663, 9673-9679, 9687-9699, 9702-9705, 9714-9717, 9725, 9735, 9737-9738 | <Any value> | |
| C700-C729, C751-C753 | 9590, 9596-9663, 9673-9679, 9687-9698, 9716-9719, 9725-9726, 9735, 9737-9738 | 3 | |
| C750, C754-C759 | 9590, 9596-9663, 9673-9699, 9702-9719, 9725-9726, 9735, 9737-9738 | <Any value> | <Any value> |
| C000-C440, C442-C689, C691-C694, C698-C699, C739-C749, C750, C754-C759, C760-C809 | 9591 | <Any value> | 3, 9 |
| C700-C729, C751-C753 | 9591 | 3 | 3, 9 |
| C000-C440, C442-C689, C691-C694, C698-C699, C739-C749, C750, C754-C759, C760-C809 | 9826-9827 | <Any value> | <Any value> |
| C700-C729, C751-C753 | 9826-9827 | 3 | <Any value> |
Notes
9590, 9596-9663, 9673-9699, 9702-9719, 9725-9726, 9735, 9737-9738, 9826-9827 (varying primary sites and histologies) * *See SSDI Manual, Appendix A: Schema ID 00790: Lymphoma for detailed listing of primary site/histology combinations for this schema* 9591 and Schema Discriminator 1: 3, 9 (C000-C440, C442-C689, C691-C694, C698-C809) **Note 1:** The following sources were used in the development of this schema * SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf) * SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/) * Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx * Chapter 79 *Hodgkin and Non-Hodgkin Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois. * Chapter 80 *Pediatric Hodgkin and Non-Hodgkin Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois. **Note 2:** See the following schemas for the listed histologies * C000-C440, C442-C689, C691-C694, C698-C809 (9823): *Lymphoma-CLL/SLL* * C441, C690, C695-C696 (9590-9699, 9673-9699, 9702-9719, 9725-9726, 9734-9738, 9823, 9826-9827, 9930): *Lymphoma Ocular Adnexa* * C440, C442-C449, C510, C609, C632 (9597, 9680, 9708-9709, 9712, 9718-9719, 9726): *Primary Cutaneous Lymphomas* * C700, C710-C719 (9680, 9699, 9702-9715): *Brain* * C701, C709, C720-C725, C728-C729 (9680, 9699, 9702-9715): *CNS Other* * C751-C753 (9680, 9699, 9702-9715): *Intracranial Gland* * 9591 and Schema Discriminator 1: 1, 2 (C000-C440, C442-C689, C691-C694, C698-C809): *HemeRetic* **Note 3:** The Cotswold modification of the Ann Arbor staging system (used in AJCC 6th and 7th editions) has been updated to the *Lugano classification*. The *Lugano classification* includes an E suffix for lymphoma with either localized extralymphatic presentations (Stage IE) or by contiguous spread from nodal disease (Stage IIE). A change from the Cotswold modification of the Ann Arbor Staging System, E lesions do not apply to patients with Stage III nodal disease; or any patient with nodal disease above and below the diaphragm with concurrent contiguous extralymphatic involvement (Stage IV), which was previously Stage IIIE. **Note 4:** Schema includes the preferred terms based on the *2017 WHO Classification of Haematopoietic and Lymphoid Tissues* 9590 Malignant lymphoma, NOS 9591 Non-Hodgkin lymphoma, NOS 9596 B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classic Hodgkin lymphoma 9597 Primary cutaneous follicle centre lymphoma 9650 Classical Hodgkin lymphoma 9651 Lymphocyte-rich classic Hodgkin lymphoma 9652 Mixed cellularity classic Hodgkin lymphoma 9653 Lymphocyte-depleted classic Hodgkin lymphoma 9659 Nodular lymphocyte predominant Hodgkin lymphoma 9663 Nodular sclerosis classic Hodgkin lymphoma 9673 Mantle cell lymphoma 9678 Primary effusion lymphoma 9679 Primary mediastinal (thymic) large B-cell lymphoma 9680 Diffuse large B-cell lymphoma (DLBCL) 9687 Burkitt lymphoma 9688 T-cell/histiocyte-rich large B-cell lymphoma 9689 Splenic marginal zone lymphoma 9690 Follicular lymphoma 9691 Follicular lymphoma, grade 2 9695 Follicular lymphoma, grade 1 9698 Follicular lymphoma, grade 3 9699 Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) 9702 Peripheral T-cell lymphoma, NOS 9705 Angioimmunoblastic T-cell lymphoma 9708 Subcutaneous panniculitis-like T-cell lymphoma 9709 Primary cutaneous peripheral T-cell lymphomas 9712 Intravascular large B-cell lymphoma 9714 Anaplastic large cell lymphoma, ALK-positive 9715 Anaplastic large cell lymphoma, ALK-negative (2021+ only) 9716 Hepatosplenic T-cell lymphoma 9717 Enteropathy-associated T-cell lymphoma 9718 Primary cutaneous anaplastic large cell lymphoma 9719 Extranodal NK/T-cell lymphoma, nasal type 9725 Hydroa vacciniforme-like lymphoma (2018-2020 only, nonreportable as of 2021) 9726 Primary cutaneous gamma-delta T-cell lymphoma (2018-2020 only, see code 9687/3 for 2021+) 9735 Plasmablastic lymphoma 9737 ALK-positive large B-cell lymphoma 9738 HHV8-positive DLBCL, NOS 9766 Lymphomatoid granulomatosis grade 3 (2021+ only) 9826 Burkitt cell leukemia (2018-2020 only, see code 9687/3 for 2021+) 9827 Adult T-cell leukemia/lymphomaData Items
| Name | Default Value | Used in Derivation | NAACCR Item | Required By | Metadata |
|---|---|---|---|---|---|
| Year of Diagnosis | No |
NAACCR #390
dateOfDiagnosis |
None | ||
| Primary Site | Yes |
NAACCR #400
primarySite |
None | ||
| Histology | Yes |
NAACCR #522
histologicTypeIcdO3 |
None | ||
| Behavior | Yes |
NAACCR #523
behaviorCodeIcdO3 |
None | ||
| Schema Discriminator 1 | Yes |
NAACCR #3926
schemaDiscriminator1 |
All | SSDI | |
| Tumor Size Clinical | 999 | No |
NAACCR #752
tumorSizeClinical |
None | |
| Tumor Size Pathological | 999 | No |
NAACCR #754
tumorSizePathologic |
None | |
| Tumor Size Summary | 999 | No |
NAACCR #756
tumorSizeSummary |
None | |
| Regional Nodes Positive | 99 | No |
NAACCR #820
regionalNodesPositive |
None | |
| Regional Nodes Examined | 99 | No |
NAACCR #830
regionalNodesExamined |
None | |
| LVI | 8 | No |
NAACCR #1182
lymphVascularInvasion |
None | |
| EOD Primary Tumor | 999 | Yes |
NAACCR #772
eodPrimaryTumor |
None | |
| EOD Regional Nodes | 888 | Yes |
NAACCR #774
eodRegionalNodes |
None | |
| EOD Mets | 88 | Yes |
NAACCR #776
eodMets |
None | |
| SS2018 | No |
NAACCR #764
summaryStage2018 |
None | ||
| Grade Clinical | 8 | No |
NAACCR #3843
gradeClinical |
CCCR/Canada COC NPCR SEER |
SSDI |
| Grade Pathological | 8 | No |
NAACCR #3844
gradePathological |
CCCR/Canada COC NPCR SEER |
SSDI |
| Grade Post Therapy Clin (yc) | No |
NAACCR #1068
gradePostTherapyClin |
COC NPCR SEER |
SSDI | |
| Grade Post Therapy Path (yp) | No |
NAACCR #3845
gradePostTherapy |
CCCR/Canada COC NPCR SEER |
SSDI | |
| B Symptoms | 8 | No |
NAACCR #3812
bSymptoms |
CCCR/Canada COC SEER |
SSDI |
| HIV Status | 8 | No |
NAACCR #3859
hivStatus |
COC 2018–2020 SEER |
SSDI |
| NCCN International Prognostic Index (IPI) | X8 | No |
NAACCR #3896
nccnInternationalPrognosticIndex |
COC SEER |
SSDI |
Initial Context
Outputs
| Name | Default Value | Description | NAACCR Item | Metadata |
|---|---|---|---|---|
| Schema ID | 00790 |
NAACCR #3800
schemaId |
None | |
| Derived Version | {{ctx_alg_version}} | None | None | |
| Derived Summary Stage 2018 | 9 |
NAACCR #762
derivedSummaryStage2018 |
None |